According to Bloomberg Ratings, the ten research firms that cover Bayer Aktiengesellschaft (OTCMKTS: BAYRY) have recommended “Moderate Buy” as the best course of action for investors to take when purchasing the company’s stock.
Bayer Aktiengesellschaft trades under the ticker symbol “BAYRY.” Six market analysts have assigned a “buy” rating to the stock, while only four have assigned a “hold” rating.
Throughout the previous year, several different brokerages covered the stock, and those brokerages projected that the stock would trade at an average price of $77.80 over the following year.
OTCMKTS BAYRY trading started on Wednesday at $15.16 and continued until Friday.
At the moment, the share price of the company is trading at $15.12, which is higher than its 50-day and 200-day moving averages, which are both set at $13.78.
In the past year, the price of Bayer Aktiengesellschaft has ranged from a low of $11.41 to a high of $18.45.
The current price of Bayer Aktiengesellschaft is $11.41.
The company’s financial metrics, including its price-to-earnings-growth ratio of 0.15, its price-to-earnings ratio of 13.07, and its beta of 1.19, contribute to its current market value of $59.57 billion.
A debt-to-equity ratio comes in at 0.95; a quick ratio at 0.77; a current ratio at 1.16; and a quick ratio at 1.16.
During the past few months, many research companies have shown an interest in BAYRY.
Bank of America downgraded its recommendation to “buy” Bayer Aktiengesellschaft’s stock to “neutral” in a research note published on Monday, December 5.
This marked a significant change from the previous recommendation, “buy.” Morgan Stanley downgraded the rating it had previously assigned to the shares of Bayer Aktiengesellschaft from “overweight” to “equal weight” in a research note published on Friday, January 6.
The price objective for shares of Bayer Aktiengesellschaft was reduced from €76.00 ($80.85) to €70.00 ($74.47), reflecting a decrease of €4.00, in a research note that Berenberg Bank published on Monday, November 14.
The note was published in the United States.
The investment bank maintained that “buying” the shares was the best action.
Bayer Aktiengesellschaft shares were previously classified as being in the “overweight” category; however, JPMorgan Chase & Co reclassified them as being in the “neutral” category in a published research note on January 3. Societe Generale gave the company a rating of “hold” in a research report that was published on Wednesday, November 9, and lowered their price objective on shares of Bayer Aktiengesellschaft from €69.00 ($73.40) to €54.00 ($57.45).
Both of these changes were made in response to recent market developments.
These decisions were made with the company’s stock in mind at some point during the process.
Customers in the high-tech materials, nutritional supplement, and healthcare industries are Bayer AG’s target demographic for creating new products, manufacturing existing products, and distributing those products.
It operates in several different business divisions, including pharmaceuticals, consumer health, crop science, animal health, and Covestro.
The Pharmaceuticals segment is in charge of the research and development of prescription medications and their production and distribution, particularly in the fields of ophthalmology, cardiology, and women’s health.
In addition to developing and selling contrast agents and diagnostic imaging tools, this division is also responsible for developing and selling specialty therapies in oncology, hematology, and ophthalmology.